For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Clover Health Investments Corp’s stock clocked out at $4.31, up 1.65% from its previous closing price of $4.24. In other words, the price has increased by $1.65 from its previous closing price. On the day, 7.54 million shares were traded. CLOV stock price reached its highest trading level at $4.355 during the session, while it also had its lowest trading level at $4.15.
Ratios:
To gain a deeper understanding of CLOV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 09 ’24 when Garipalli Vivek bought 531,700 shares for $1.88 per share. The transaction valued at 999,596 led to the insider holds 1,409,267 shares of the business.
Garipalli Vivek bought 877,567 shares of CLOV for $1,000,426 on Jun 17 ’24. The Director now owns 877,567 shares after completing the transaction at $1.14 per share. On May 16 ’24, another insider, Loengard Anna U, who serves as the Director of the company, bought 17,085 shares for $0.96 each. As a result, the insider paid 16,372 and bolstered with 15,600 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 2159779840 and an Enterprise Value of 1826860800. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.40 while its Price-to-Book (P/B) ratio in mrq is 6.09. Its current Enterprise Value per Revenue stands at 0.864 whereas that against EBITDA is -23.699.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.00, which has changed by 3.3309498 over the last 52 weeks, in comparison to a change of 0.24359846 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.71, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is 26.67%, while the 200-Day Moving Average is calculated to be 80.51%.
Shares Statistics:
It appears that CLOV traded 6.02M shares on average per day over the past three months and 7122220 shares per day over the past ten days. A total of 394.44M shares are outstanding, with a floating share count of 376.30M. Insiders hold about 24.91% of the company’s shares, while institutions hold 16.40% stake in the company. Shares short for CLOV as of 1735603200 were 15956062 with a Short Ratio of 2.65, compared to 1732838400 on 15276865. Therefore, it implies a Short% of Shares Outstanding of 15956062 and a Short% of Float of 3.9300002000000003.
